(Q37003217)

17 August 2017

1 reference

title

Oxidative stress as a cause of Parkinson's disease (English)

1 reference

17 August 2017

1 reference

0 references

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

29 November 2022

author name string

P. Jenner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1801537

29 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1801537

29 November 2022

publication date

1 January 1991

1 reference

full work available at URL

17 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0404.1991.tb05013.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0404.1991.tb05013.x/fullpdf

29 November 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Acta neurologica Scandinavica. Supplementum

29 November 2022

published in

1 reference

17 August 2017

136

1 reference

17 August 2017

6-15

1 reference

Striatal function in normal aging: implications for Parkinson's disease.

17 August 2017

3

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Ageing and Parkinson's disease: substantia nigra regional selectivity

29 November 2022

4

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

The role of environmental toxins in the etiology of Parkinson's disease

29 November 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Xenobiotic metabolism in Parkinson's disease

29 November 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

S-methylation in motorneuron disease and Parkinson's disease

29 November 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

29 November 2022

8

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

29 November 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

29 November 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

29 November 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

29 November 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

29 November 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Effect of long-term administration of 1,2,3,4-tetrahydroisoquinoline (TIQ) on striatal dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) content in mice

29 November 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products.

29 November 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

29 November 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

29 November 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP

29 November 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B.

29 November 2022

22

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

29 November 2022

23

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain?

29 November 2022

25

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles

29 November 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.

29 November 2022

28

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

29 November 2022

29

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes

29 November 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium

29 November 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo

29 November 2022

32

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment.

29 November 2022

33

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse.

29 November 2022

34

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Transient nigral ubiquinone depletion after single MPTP administration in mice.

29 November 2022

35

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Parkinson's disease: a disorder due to nigral glutathione deficiency?

29 November 2022

37

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients.

29 November 2022

38

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Reduced and oxidized glutathione in human and monkey brain

29 November 2022

39

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Postmortem changes of amino compounds in human and rat brain

29 November 2022

40

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease

29 November 2022

42

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

LIPID PEROXIDATION AND PARKINSON'S DISEASE

29 November 2022

43

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Brain Peroxidase and Catalase in Parkinson Disease

29 November 2022

44

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Glutathione peroxidase activity in Parkinson's disease brain.

29 November 2022

45

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra

29 November 2022

47

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Mitochondrial complex I deficiency in Parkinson's disease

29 November 2022

48

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

29 November 2022

49

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

29 November 2022

50

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE

29 November 2022

51

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease

29 November 2022

52

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence

29 November 2022

53

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Mitochondrial DNA analysis in Parkinson's disease

29 November 2022

54

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect

29 November 2022

55

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Studies on Parkinson's Disease Including X-Ray Fluorescent Spectroscopy of Formalin Fixed Brain Tissue

29 November 2022

56

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

29 November 2022

57

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease

29 November 2022

59

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Brain iron and ferritin in Parkinson's and Alzheimer's diseases.

29 November 2022

60

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains

29 November 2022

61

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Distribution of arsenic, manganese, and selenium in the human brain in chronic renal insufficiency, Parkinson's disease, and amyotrophic lateral sclerosis

29 November 2022

62

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis

29 November 2022

63

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains

29 November 2022

64

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Decreased ferritin levels in brain in Parkinson's disease

29 November 2022

65

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Ferritin in the cerebrospinal fluid of patients with Parkinson's disease

29 November 2022

66

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid.

29 November 2022

70

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Ascorbic acid reduces the dopamine depletion induced by MPTP.

29 November 2022

71

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion.

29 November 2022

72

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse.

29 November 2022

73

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment.

29 November 2022

74

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

MPTP toxicity in the mouse brain and vitamin E.

29 November 2022

75

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Induction by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of lipid peroxidation in vivo in vitamin E deficient mice.

29 November 2022

76

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.

29 November 2022

77

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

29 November 2022

78

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse

29 November 2022

79

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

29 November 2022

80

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice.

29 November 2022

81

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

29 November 2022

82

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

29 November 2022

84

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

29 November 2022

85

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

29 November 2022

86

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

29 November 2022

88

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Effect of deprenyl on the progression of disability in early Parkinson's disease

29 November 2022

89

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

29 November 2022

90

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

29 November 2022

91

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

29 November 2022

92

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05013.X

29 November 2022

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1801537

29 November 2022

1 reference